A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer

• Status: Completed
• Trial end date: 2020-10-21
• Target enrollment: 0
• Participant gender: All

Summary

The study is investigating the efficacy and safety of UroGen's UGN-102 to treat patients with Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at intermediate risk of recurrence.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UroGen Pharma Ltd.

Criteria

Inclusion Criteria:

1. Willing and able to sign an informed consent and comply with the protocol.

2. Has newly diagnosed or historic LG NMIBC (Ta) histologically confirmed by cold cup biopsy at screening or within 6 weeks of screening.

3. Is at intermediate risk for progression, defined as having 1 or 2 of the following:

• Presence of multiple tumors;

• Solitary tumor > 3 cm;

• Recurrence (≥ 1 occurrence of LG NMIBC within 1 year of the current diagnosis).

4. Has negative voiding cytology for HG disease at or within 6 weeks of enrollment.

5. Willing to use 2 acceptable forms of effective contraception from enrollment through 6 months post treatment if the participant is female or the female partner of a male participant and is of childbearing potential (defined as premenopausal women who have not been sterilized).

6. Has adequate organ and bone marrow function as determined by routine laboratory tests as below:

• Leukocytes ≥ 3,000 cells per μL;

• Absolute neutrophil count ≥ 1,500 cells per μL;

• Platelets ≥ 100,000 per μL;

• Hemoglobin ≥ 9.0 g/dL;

• Total bilirubin ≤ 1.5 x upper limit of normal (ULN);

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN;

• Alkaline phosphatase ≤ 2.5 × ULN;

• Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min.

7. Has no evidence of active urinary tract infection (UTI) at Screening and Baseline visits.

• In the case of symptomatic UTI, the patient will be treated with a full course of antibiotics, and study medication will be postponed until resolution. In the case of asymptomatic bacteriuria, the use of prophylactic antibiotics and postponement of study medication is left to the discretion of the Principal Investigator (PI).

Exclusion Criteria:

1. History of carcinoma in situ (CIS) on preliminary cystoscopy within 5 years of enrollment.

2. Received Bacillus Calmette-Guérin (BCG) treatment for UC within previous 2 years.

3. History of HG papillary UC in the past 2 years.

4. Known allergy or sensitivity to mitomycin.

5. Clinically significant urethral stricture that would preclude passage of a urethral catheter.

6. History of pelvic radiotherapy.

7. History of:

• Neurogenic bladder;

• Active urinary retention;

• Any other condition that would prohibit normal voiding.

8. Past or current muscle invasive (ie, T2, T3, T4) or metastatic UC or concurrent upper tract urothelial carcinoma (UTUC).

9. Has participated in a study with an investigational agent or device within 30 days of enrollment.

10. History of prior treatment with an intravesical chemotherapeutic agent with the exception of a single dose of chemotherapy immediately after any previous TURBT.

11. Has an underlying substance abuse or psychiatric disorder such that, in the opinion of the investigator, the patient would be unable to comply with the protocol.